Gossamer Bio (GOSS)

Bryan Giraudo CFO
Sheila Gujrathi Co-Founder and CEO
Ying Huang Bank of America/Merrill Lynch
Joseph Schwartz SVB Leerink
Josh Schimmer Evercore
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.

Good morning, and welcome to the Gossamer Bio First Quarter 2019 Earnings Call. Today's call will feature updates from Gossamer Bio management's team followed by a question-and-answer session. I would now turn the call over to Gossamer's Chief Financial Officer, Bryan Giraudo. Bryan?

Bryan Giraudo

Thank you, operator and thank you all for joining us this morning. call Co-Founder today's Officer, Chief on Dr. me is and Gossamer's Executive With Gujrathi. Sheila Gossamer release XXXX Earlier results a this issued morning press corporate first ended a for quarter announcing March provided XX, and update. the financial its note today covered call of Private under on Act. Reform provision is Securities Harbor certain Litigation discussed Safe Please that the the information the We forward-looking statements. making caution will management be listeners that Gossamer’s during this call associated to with or Actual company's results implied stated risks may and statements forward-looking those uncertainties differ by due the business. materially these from These are Gossamer's and report statements news subsequent the releases, XX-K annual filings. Form forward-looking the qualified statements contained SEC in filings on and including This limited conference may a period that of information time. contains call time sensitive only be accurate for also looking date events circumstances Gossamer to no this Bio of undertakes obligation to forward after or statements the revise call. any conference update reflect or

Now it turn I with over wonderful to of all remarks, Sheila? will those Sheila.

Sheila Gujrathi

oncology. of hand clinical a us months walk for soon quarter. Thank everyone which go and programs, On to updates for you, I call. joining in back to start becoming I we've exciting today's milestones, immunology, achieved February, time we and for then in today’s and to through towards to and an closed XXXX. be call recent am good to goal over leader Since Bryan moved Gossamer Bryan over will our especially busy results phase financial IPO been our going it the our rapidly on you The had and inflammation, product morning have have in

readouts foundation expected We multiple XXXX. for a data are setting this year in

spontaneous which and being and advanced with condition clinical chronic other developed without rhinosinusitis and oral our for with DPX product phase start chronic asthma polyps most candidate nasal me and including, urticaria. both allergic eosinophilic GBXXX is antagonist Let

support at interim trigger known Gossamer that of in of remain XXXX a XX, presented previously and to throughout enrolling half track Findings The first have results February FDA. as study analysis doses is XXXX. begin to Phase on and positive, useful of interim Phase GBXXX two severe half In of worsening. the first study. also Francisco Dr. with meeting study we patients the plan our in to single Ortega the San its moderate known on leading as of partly exhaled at the placebo background controlled asthma. XX is in analysis Nitric subject who to LEDA we as of of to is one treatment eosinophilic marker development moderate and trial All for the GBXXX. LEDA in we NDA is X Hector patients trials prognostic of GBXXX could milligrams announced, first Xb legislation design testing the in against response in asthma to mild currently and known is study Fractional a XX the Oxide compositor atopic study a asthma as FeNO post-hoc study XX-week endpoint three serve primary with presented AAAAI the GBXXX analysis If a patients will therapy remain the As

to as saw patients elevated as control patients baseline as we addition mark analysis FeNO reductions asthma to to FeNO with compared In and In study. we high lung FeNO. currently in the a levels, involve a in is to function relative well using baseline numeric LEDA eosinophil with in low which improvements marker greater placebo

results the We implications development are potential each excited of about these GBXXX. and of

strategy in could our developed execute conditions be by X to GBXXX started other also Type allergic potentially driven GBXXX cytokine biology have We where first-in-class.

X in TITAN Phase know filling and as you our inform chronic study. to rhinosinusitis we We a begun that patients are have also proof-of-concept study excited

to effect designed intranasal playing will unmet refractory a study sinonasal later XXX GBXXX patients of on SNOT-XX or for is dose the to the patients measure in This patients score, patient in polyps who high weeks The of are study treatment which not first asthma with of outcome enroll after XX endpoint the to test treatment steroids. the intranasal patients such feeling has as without both or the of with vast a polyps of and to study secondary of we represents key approximately options square on population irrespective polyps to specific without the in plan which second with relevance effected in populations significant expect with nasal also both We both patients TITAN polyps the nasal nasal steroids. overwrap We enroll need patients to with for as respond plan accepting quarter. polyps endpoint. to endpoints

in We XXXX. done study expect to be this

the in approved therapy. are we poor the in injectable proof-of-concept year. Phase available and antihistamine study chronic Patients later or GBXXX have to with another little track urticarial only spontaneous of Xolairas who don’t X CSU to quality respond those life is biologic Additionally, CSU this initiate of to with

expect readout also to We XXXX. that in trial

are and forward for allergic the heavy look very across rich the program. to the GBXXX be indication we of multiple by as We XXXX potential for choice year treatment excited to data oral the

unmet for on now candidate Arterial Hypertension as need. inhaled the known PAH. treatment an orphan we PDGFR our clinical-stage adverse is Inhibitor, move which high are of Let’s to product medical second also of disease GBXXX, event has PAH developing Pulmonary

toxicity in the was was designed to inhibitor marketed was Phase developed ultimately Imatinib GBXXX currently the Gleevec. that lungs therapies safety brand formed has believe very patients PAH While the the selective to which is the efficacy be imatinib and is Gleevec could in GBXXX promising locally we but in culmination believe seen in concerns against further receptor serious clinical therapeutic GBXXX classes and potentially against class activity use which there present cells multi inhaled provides as of delivered have in is study, systemic we of with the other are first for to in it are indications attempt that be and important name currently believe the could c-ABL the kinase for demonstrated powder the prudent against kinase PAH. drivers those to and avoid potential over not had such after we developing IMPRES vasodilator progressive oncology binding PAH We design by available under X study a a spare simple inhaler To imatinib, arteries growth and imatinib. which the main PAH hampered vessels toxicity. in a exposure with also on disease address by patients, PAH disease. blood effects the a promising patients. c-KIT the where therapeutic modifying systematic new fatal drug of provide disease pulmonary inhibitor of as activity target doesn’t inhaler. three the GBXXX results PAH GBXXX an dry adherent are often PDGF of rationally remains that the BCR patients. to

We safety well and Phase those no tolerated dosing have with with healthy disease. GBXXX events completed with significant normal studies of was GBXXX and adverse X volunteers and

up Xb study year. XX We later hope in first patients in begin site initiation to initiate and and to an and screening anticipate in generate half of Phase followed the two study and our to explorer of interesting we PAH later week Xb the to to translation read-out open-label quarter. expect patient by we The H translational patients We which second plan from Phase XXXX. be for biomarker engagement the will our target a extension this measures and

inhibitor tissue oxygen demonstrated involve healing GBXXX promoting are our or mechanism IBD HIF-Xa, IBD ulcerative mucosal our which IBD to Moving crowd barrier patients, gut-targeted third colitis excited experience and thus we including Inflammatory program teams treatment significant perpetually the remain of we the asset, to lower to low It Disease epithelial design list preclinical know a right contributed including are of given barrier our dues unmet of valid functions, HIF-Xα been levels believe clinical Ozanimod along clinical GBXXX Bowel is than process. long-term novel pursuing. protective low space number levels. oral stabilize a patients. to an normal for the of neurogenic we preferentially that intestinal clinicians the transfusion inflammatory and involved is administration an is mechanism mucosal IBD there we there distraction is and the and GBXXX increasingly and protective UC. for have In are of a stage resulting is designing various disease very prolyl differentiated oral and reducing been in in healing for well is oxygen hydroxylase in clinical need of model, a by Stabilizer ultimately these very therapeutics admissions present has reconstitution spoken response healthcare The patients HIF-Xa software for IBD stabilization still inflammation mucosal.

unique of model. While a of and we than barrier that immunomodulatory active GBXXX is potentially repair have it function some preclinical important also mechanism. effects is enhances rather in and not epithelial immunosuppressive change purely mechanism GBXXX action

DC. we Phase cleaning Phase X begun we As active trial moderate active we in volunteers of Xb outside that have and are healthy to to with very in pleased studies in IND now running U.S., an have are mild announce patients a

study expect in patient first quarter. the to the our in dose second We

symptom UC activity and of to We dosing gene We will and in half The study the expressions preclinical on that XXXX. improvement. weeks will and for completion begin an potentially patient this epithelial dosing based barrier studies. of following have anticipate weeks increase demonstrate the in changes initial and potentially targeting to four trial patients of eight length restoration the UC designed first readout engagement,

cancer. generated Finally, about are data and GBXXXX it model. of first preclinical is difficult treat to and GBXXXX very immuno-oncology our the our oral candidate has for treatment tumor the is modulator CDXXb product excited we

the type a immune that on in to key suppressor tumors such on proven depressive to either TAMs them those is immuno-oncology made state. macrophages, The and importantly response. of or a in suppress and I cells CDXXb maincheck immune or of focus pre-clinical or in think by depolarize visits into both also point strategy trafficking reduce Myeloid-derived cells recruited modulation GBXXXX anti-CDX therapy. tumor converted reformatory forms studies secondary At to of tumor immune and MDSCs resistant tumor-associated factor primary as Our the from cells state or have

consists therapy stage into look immunosuppressive a with candidate or recommended of year. needs. as product It of out all been of dose targeting building dose chemotherapy. biology protocol same Phase to combination were escalation study or These monotherapy expression and breast. are cells high in second later greater types in Phase therapy clinic the open has the X cohorts by second of months metastatic half PD portfolio colorectal, X anti-PDX the clinical we X made escalation and cancer, reach FDA diverse plan to assets X FDA positive we unmet or anti-CDX chemotherapy with review dose, gastric indications Phase in a line proud multiple our and plan cancer, We IND very to of including GBXXXX the team and done Phase three XXXX. tumor we in the have indications tumor gastric, gastroesophageal our investigate this few esophageal, bringing the greater negative the X/X microsatellite solid or the line stable portfolio subject triple or to add first advanced pancreatic type busy initiate of work proud to study to in X/X The our study have to with followed progress and Phase will a we pancreatic, in we The tumor of portion and recently CDXXb GDXXXX GBXXXX When a expansion of forward very GBXXXX and prevalent. submitted am we second I cancer. colorectal are line has

all would back like website to call a to join. over financial Gossamer those the the back Healthcare I that afternoon And for the also hosting now the the highlight turn America/Merrill I Bryan? event for be call Page live chat Lynch to Please for to of that, Giraudo update. Bryan want Investor who at Bryan, turn X Eastern that will Bank Bio would like fireside further Time on webcast see will I With we this Before p.m. over be to a at Conference. details.

Bryan Giraudo

for you, activities a the over past results Thank give quarter. Sheila. the our will brief summary few I months of before financing over the going

net over As initial offering announced closed raised in February, proceeds. million in we we previously in our which $XXX public

accreditation. closing lead to close facility of we XX taken $XXX agreement certain by of and our was will the available the subject of Following million clinical XXX Financial. million facility customer at be debt MidCap the IPO milestones that other million achievement the announced development to down and of Gossamer a

position cash of our a with With is the runway financings these very half into two second in Gossamer strong cash extending XXXX.

first in stock In and quarter. costs the a process the expenses consists of million in which $XXX.X up received proceeds quarter quarter the facility. expenses our which equivalents ended We related $X of GBXXX. quarter initial for to the in the on not of licensing million in MidCap included million also and compensation. and reflect securities does with This approximately financial $XX Now $X quarter, the that the following which ramp in GBXXX, the cash nearly approximately at were candidates of the GBXXX interest $XX million reflects were Research million million a receivable were acquisition cash with the we to R&D we expenses, signing receive for quarter. which development results product the $X of and G&A end. based expenses of

to the to Our offer Sheila and for per Sheila? line questions before net that, With call turn comments the $X.XX equating back for over loss some to the share. we open million answers. up I'll the $XX.X was closing quarter

Sheila Gujrathi

have Thank potential families. of at you, in Bryan. we are candidate At Gossamer multiple vision also developing incredibly believe lives to that great the our their products realizing the who Bio. proud generated have with We're significantly team and thrilled our was momentum better Gossamer the patients our of Bio, we we

join allows I caregivers, to taking to begin physicians, With the turn the time and that, of continued science the question-and-answer Thank will over for to support. strong us for alike. you now today and patients, for to shareholders financial the the position Operator? advance employees session. your Our call our continue operator benefit us to


first And question our with Instructions] Ying Lynch. of [Operator comes Huang America/Merrill from Bank

Your line is open

Ying Huang

Sheila. maybe So a ones for quick two

slightly looking all result the of been to from for one forward clinical different. X on the trials Phase batch First from is data the Novartis investors first

guess think through obvious, that secondly, So GBXXX negative should talk if X on GBXXX,which how for the about different and will advantage in you read about the completed Is it mean talk from PD then need took here. development no dose is And for against it's why have can besides our the comparative guess, capacity may of is the and that - healthy you what we fact you or is in terms come positive, findings then can cash PK from response the trial? about ongoing for to SAE Bryan, you you I trial Phase quickly can GBXXX ending is which additional And about that you I financing then support volunteers, not. talk slightly kneecap. because you

Sheila Gujrathi

questions. Great you. Thank Yes.

with start batch Novartis let's So studies in the programs.

We are readout. data looking Phase X much their forward also to very

Phase later everyone, to of Phase large are four Just X consisting asthma, of they trials those program year. remind X out Phase reading X have a six this actually trials within

their of In still on terms guidance recent is track. that

out September two trials out around reading in exacerbation December will in function SAE So one we and reading to have and are anticipating they trials timeframe then to be one that November.

luster trials be deal that are the leading So up. will these and

that in are mechanism moderate is the with incentive of including of DPX positive those antagonism. the that population, a patient severe so so trials asthmatic of subgroup high much very And if validation

And so would through program, a the similar I - we read action program of positive both that because share. that to be think our mechanism are of

antagonism the adult even that And primary very severe of for terms think view way or forward they and of that both which PH to into subgroup be have with their is relevance the high broad and data, are do positive consistent that much a endpoint moderate stated activity clinical very they case we asthma we is there GBXXX. or in to So their GBXXX, that but and X biologic other we looking know going highly population, the base subgroup. is on will where

Now, points differentiation of have of we fevipiprant. some do

is We have a molecule receptor. have infinity high the that which very potent DP-X to we and collective GBXXX binding

DP We footprint. study which is also been a greater reflector prolonged have resistance has than what time

of those DPX Novartis over XX that they a inhibit to XX importantly, and would characteristics hour important and think than levels. very to the we do XX And XXX We think mechanism have exposure time. period action are milligrams better in have receptor XXX has clinically we efficacious and PK to their to - of we go receptor we publishes for be here and dose internalization GBXXX up able effective also very manner. with about think the a really reach very residence for PGDX we that's minute dosing different, it are we as that to minutes that achieve and actually later coverage much around lower to think XX and

there could clinic efficacy that potentially their in So maybe is case in better really marks. the meet the that and doesn't we potential a show different

are for So very GBXXX. for those important characteristics us,

efficacy X watching coming course, the safety half data data anticipating we clinical will profile to closely in trial. followed readouts We seeing the what XXXX of of of by full later out see the is first interim be our Phase and fevipiprant year. the are that greatly And

first So move question to the question. GB for I there am that's second the the on going With to the follow and that, up.

PK formulation multiple On Phase clearance. systemic cohorts. was into a GBXXX. volunteer normal absorption of we're are and trial finish coming profile we we fast dose that we dose study again healthy and very cohorts of obviously but us was rapidly And seeing pleased are Yes out finish a the the exciting GBXXX for the X circulation single seeing very with with because of into that took inhaled that

a the have we life. half short So

out. that see is for upon make dose us to dosing ruling important were what's that We which not do we multiple also sure accumulation

regimen compared is looking I Phase the dry confirmed see we Xb to was that the do characteristics tolerability being and we in want we're very profile to forward that, lungs adverse dose in to systemic PK really and the to the volunteers. and healthy in now events the compared the clinic you differentiation very PAH that inhaled again, hand confirm healthy trial lung normal the powder higher fold in we're formulation exposure really the taking the systemic the exposure a robust efficacy tolerated. increased patients the Bryan. this to So us significant expect into have of and remind which With and to I’ll And safety formulation exposure that the to normal nice minimize seeing is well exposure, profile - several have crux just systemic data so, that volunteers not well where again the inhaler over it to we in that's maximize tolerated very for And very is being and toxicity. confirming any a

Bryan Giraudo

the amount that to XXXX. that the to means purely Jeff. place as Yes, very, a regards runway midcap taking the was sufficient of in question well ensure very We into put

want we on As could that next I to be seven and had to that year, balance would the investors that milestones those of to council. milestones of level said work make sure sheet, news the target to robustness able be with our clinical we next still the deliver communicate and

So to it really long a access means to runway and term ensure capital.


our SVB Leerink. Schwartz with from question And comes Joseph next

Your line is open.

Joseph Schwartz

spaces the to like seems I urticaria. nasal you've and without you in activity polyps chronic into, talk spontaneous of could wondering the GBXXX these rhinosinusitis with see been too. has enough you've has newer if looking some going outlined across development more such areas in been signals in some of was pharma if as chronic for It that about

of in increased the challenging as activity So way. a may any execution

Sheila Gujrathi

after chronic rhinosinusitis, are is only additional excited in we're which that, urticaria Yes. Well moving into we're or polyps with about we really space it actually the without and again, white area. Thanks, going more disease these forward chronic the oral, Joe. and indications

polyps populations. rhinosinusitis, designed with start with and really without is here again the both involve I'll patients to So, or chronic study in

measures. the a looking consider of sense obstruction, the meaningful of either is looking outcome for XX be patients patients. for congestion, it really we're that patients with loss questionnaire. symptoms symptoms now a lot measure, we improvement at a these pertinent Now very including nasal going And and that gets other or primary that clinically endpoint point without busy what of smell which polyps nasal relevant is outcome clinical these at debilitating that's really are outcome And to looking those very because have for XX and

a this brought at be as addition In at time. trials, this will Phase application with looking that X actually the and validated review has the as polyps a priority diplomats been has being under endpoint is is diplomat applied in as DLA mentioned, supplemental I we and that accepted forward to nasal their score FDA

of as well the have And obstruction nasal and for. at endpoint so nasal congestion looking they at the looked reduction as polyps

very is that keen patients so subgroup the in of that have something nasal we're And to also understand that polyps.

looking meaningful we or polyps improvement well. So, score again that in are reduction clinically we nasal for as what consider

area we CT and which sinuses So life terms of to how this are outcome oral looking in we're at in quality of emergency reduction that exacerbations at things so exacerbation, coming aspects chronic requiring or rhinosinusitis but about asthma. room a steroids exciting. very chronic number of of also severe measures we nature and visits of of rhinosinusitis outcomes, similar think is out of with of question really scan that the CT. at other pacification We're We're have the exploratory looking at the looking looking

and So, different a we're amount different these in to going all we'll and two both there's be at, populations. really again robust on nice significant populations study whether -- driving activity from we our between of level the biology that looking a that's PHX here get perspective think read employees and of

So that that think makes we sense.

really significant just the pretty especially second oral. chronic the asked know now, you of right out urticaria and the Now competitors there enrollment with were we rhinosinusitis, about chronic indication challenges. again With don't excited any we’re of

timeline. think and our we enroll we that trial can So, in say

significant concerns to have that are screening excited very again at the quarter. point. here patients don't and So we begun And any involve in patient have later

development -- pathway pathway. validated well again, urticaria Chronic So

do large biologic coming are exploratory they're and the there work and generation two X We Ligelizumab, next antibodies Novartis some Phase urticarial. have there - other anti-IgE from approved within trials forward there.

the test. activity at And so looking we’re here score seven and urticaria urticaria control

read urticaria's pretty or And And get and sample be do a so don't very what improvement relevant to Phase we and a very would activity good think have in here program, is of actually idea pretty large large is a lot oral. on And X symptoms. of size a clinical excitement in good we in do while a forward again there have clinically we efficacy. significant Ligelizumab a going study around

you a cell are so And biology, of inhibitor the especially to within key that is lot BTK and we comes urticaria. which when a there studying cell there's the basal excited being is receptor of know, function urticaria the as DPX are But well. types around inhibition it excitement that cell

receptivity good very getting the we don't anticipate trial. space and KOLS recruiting we're in investigators this a and challenges significant in So from

Joseph Schwartz

I analysis to on analysis the one the the data think evaluate first What is if in ask is analysis and half for interim that And in opportunity could two guided versus you Asthma I any the adjust final interim GBXXX and will XXXX. analysis? of course the there for between

Sheila Gujrathi

I they’re data site pretty think Yes, study. substantially readout. a is This robust

have really look So XX sXXX than that the weeks. additional patients. analysis course, we'll endpoints. of data a varying about duration even number of to of worth designed we’ll And patients a data. They'll will efficacy it’s XX have across more of at have have weeks interim In less

clinical a composite other measure, trials use, then similar what Phase like. look in X outcome of where different X, and clinical worsening course primary our will at we very that’s measures worsening, of endpoint trials so to a exacerbations, function of So medication at rescue lung the Phase and is looking studies asthma you and

each of as at measures we'll at that at measure. then lung of the look totality course PK as worsening flows as of will as by exposure. reduction well safety FEVX and Then each asthma number point, tolerability measured of composite a So outcome other we'll well look as peak of we the look subcomponent function

trial. think And type from data so I the get about readout that pretty excited of we'll we're robust again

to and positive course analysis the to design be helps administrative data XXX program may will conduct capitalize analysis go really into X the an seeing actually the planning initiation now of in on to really Now It's XX really and data if of or Phase on of data recruitment with full trial. the robust allows we're Phase Phase the continue patients the want the is for designed and worth that us readout right we of pursue Xb and not weeks with that us efficiency is more this Phase and X to operational X Xb recruitment Phase and the the allows quickly change trail.


with next question our comes Barclays. Geoff Meacham from And

Your line is open.

Unidentified Analyst

for about you're you capture This to they percentage taking asthma. intermediate or moderate as Jeff. physicians and can in is of before for to asset Scott I'm on the persistent moderate integrate yourself maybe Thanks what the move question. directly XXX define persistent Thanks. before our going the Have commercializing market biologics thought get for just that closer are patients wondering category. that you in severe to you persisting severe and category the how

Sheila Gujrathi

really Really, questions. great Scott. Thanks,

that think this this think type that But don't of much frankly a looking to their is insight, quite patients really to where at of is lot and biologics. pretty actually control opportunity your adequate need. and controller asthma and a even looking in a really in we not X go and database - and exists we do they They're market market are spending vary we are is ICS, They unmet robust including a is GINAX analysis getting corticosteroids or inhaled considered of being amount for are on inhaled And not to that medication, that the addressed continuing substantial understanding the being do are adherent We biologic aspect of on time not bit into think therapies point. really rates market have that we're moderate adherence very there the at despite one symptomatology, other poor. want access GBXXX high more there have that available by it's the corticosteroids today. manner and of claims, as and approved of to

non-adherence you that a allergist, As a XX% of are think who oral treatment. as non-compliance. with And what really pulmonologist call we who well care of there’s physicians actually and could of mix also understanding we rate these the see do physicians, target patients know, an care we who subgroup take or and primary

anticipated patients biologics, infusion so needed our by that and profile we the will be not positioning convenient day where improved robust - a to is tolerability around and physician. we really administered does think office. and their or efficacy, is And prescribing in that and administration will of once it that have not that similar And and really injectable oral greatly it's require again, safety

we we idea - have that getting and So, asthma significant comes a terms that's numbers market of more better how a of potential before moderate to category on severe target a patients. in think of the persistent persistent we're


Josh comes question next our And from with Schimmer Evercore.

Your line is open.

Josh Schimmer

the Thanks taking questions. for

of year inflect considering capacity additional question, And that have company optimal and about markers. you're gene the is points if with trial that to XXX, expression in biomarkers advancing so over for timing on the Thanks. next same you of or Phase number for you addition those of the for in the question specific relevant you're third for really the signal elaborate that your can the the X on how having. the going of XXX, of a program. that or then looking thinking effects efforts direction The are that measures of First disease terms will magnitude the the data

Sheila Gujrathi

happy Thanks, little a Josh. to bit expand that further. I'm Yes,

also we we or study number study XXX, of activity efficacy have biomarkers imatinib. seen and for that in a very Xb actually the we So Phase where have with can translational good interesting

those those actually in facts on of terms of markers. there, there's So, precedent characterization some

very which is the level So the patient the space in Peptide, is heart which marker real what is call right Brain NT-proBNP, important we this Natriuretic a strain a marker population. in

so levels and we're nice And biomarker very some own our seen animal very in show seen proBNP key we've Again that's the which greater excited imatinib. reduction nice about and what with We've in models. reduction actually imatinib preclinically a that studying. than proBNP in

us. key a marker that's So for

exceeded and understanding at heart very for and in movement is strain a to PAH, In cardiac so as important can efficacy function, measure And especially are and know addition, cardiac to and non-invasive probably of us. right echocardiograms you some mass lot imaging a very in look be imaging helpful muscle MRIs relevant the

with the expression profiles, continued gene measures. again And we target be treatment is and I imaging the think measure field that of at we're which looking more get so, towards engagement be PDGF these robust key at, that's looking then are we're especially some patients. other And going to at MRI But that other from leaning here outcome at another a more assays Kinase. we'll looking

may us So of engagement. again idea give we target just an

exposure we'll of so, especially, I biomarker think achieving lung a clinic. the to pretty think and at, group And that high the the with assess we results clinical activity nice looking in we'll be see be

XXX on few. again jump a as target some that as X, alpha and this there's is data normal we looking in seen volunteers population. get been to we've some gene well And biopsy, target I'll here there I'm we saw alpha healthy expression, where some preclinically. have even So, looking Phase at signature the chronic HIF-X actually levels this nice engagement that engagement data. at looking really exciting a we HIF-X at

if And pathology the so To what histology study and at can because we'll see population they who that robots. is we to and the active think we're time, histopathology so is that study, something index, we're have there, get ulcerative on patients continue patients screening. over on only into up by active enrolling impact histology have that's that looking colitis the a

we're be or mail some With that's flexible be sigmoidoscopy, that'll nice looking able be the eight score. or to weeks again of doing where measure and a either of really mucosa clinical assess timeframe we'll really colonoscopy at the because we'll start directly induction treatment endoscopy four improvement. and then seeing can activity So, we clinical of the

trial. of be lot of out Phase a data coming that So will Xb

lastly again on exciting half we development, by development. we are get from first business perspective business studies active nice and So continuing we And do some then our should pretty of to data think XXXX. readouts

You are right.

We clinical number of on are executing programs. a

focus generating that our has the where data really across as the same be milestones and and And XXX are not we're focused three on as execution will we out really to have our that's as readout pipeline but on right we only clinical meet of so very meaningful GBXXXX. sure that GBXXX data we readout. well data, make in And will in indications, our timeframe been programs now, that coming these on

are programs of top obviously portfolio we're pipeline we're that very programs at late XXXX those to guided a research and a active we in arena get primarily business the that XXXX we timeframe. that looking So a mind. lot will and in inquiries coming that be let Where see that But, do research our effort. we'll and clinic now and right are we interested stage and in. into to have lot programs development on of of We that

I innovative. by known at target think would think development or that a our really efforts about really be be biology that's looking that to either think where us that the programs differentiated we're truly we most biology have is excited business that we So been, of we that could novel

So to we we're hoping as of conclude those continue deals. some those to and announce pursue efforts


And there to further the the queue. any back in questions other are remarks. turn Sheila like for no call to I'd

Sheila Gujrathi

you joining on us Well, everyone for call. thank today's so much

pulling here, I all entrepreneurial a and support for on way Gossamer high day. as those a lines, with engine Bio as look build that clinical innovative excited our and first is very together our We all like to a programs - the ability lot this you earnings really an And we we've we're to quality. call we're to is quarterly nimble Thanks efforts as Bio what this everyone. our with that on thank but forward continuing show very trying as great making along really do said material Have and to and execute amazing getting Gossamer together, this folks are to that profits development basis really can always team really in research call. you the a the on and to the really well


Ladies and gentlemen Everyone thank you have for participating in today's conference. This concludes great today's program disconnect. you day. a may all